These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16001243)

  • 1. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
    Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
    Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
    de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
    Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
    Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
    Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
    Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F;
    Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
    Blaise DP; Michel Boiron J; Faucher C; Mohty M; Bay JO; Bardoux VJ; Perreau V; Coso D; Pigneux A; Vey N
    Cancer; 2005 Nov; 104(9):1931-8. PubMed ID: 16178004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second allogeneic stem cell transplantation in myeloid malignancies.
    Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
    Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
    Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
    Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
    Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.
    Anselmo AP; Cavalieri E; Meloni G; Alimena G; Cantonetti M; Maurizi Enrici R; Tosti ME; Falchetto Osti M; Gianfelici V; Mandelli F
    Haematologica; 2002 May; 87(5):507-11. PubMed ID: 12010664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
    Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
    Ferrara F; Palmieri S; Pedata M; Viola A; Izzo T; Criscuolo C; Mele G
    Hematol Oncol; 2009 Mar; 27(1):40-5. PubMed ID: 19206083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation in patients with high-risk plasmacytoma.
    Jantunen E; Koivunen E; Putkonen M; Siitonen T; Juvonen E; Nousiainen T
    Eur J Haematol; 2005 May; 74(5):402-6. PubMed ID: 15813914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
    Glossmann JP; Staak JO; Nogova L; Diehl V; Scheid C; Kisro J; Reis HE; Peter N; Engert A; Josting A
    Ann Hematol; 2005 Aug; 84(8):517-25. PubMed ID: 15759115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
    Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
    Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.